# Livestock Vaccine Market

> Livestock Vaccine Market Research Report By Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, DNA Vaccines), By Livestock Type (Cattle, Poultry, Swine, Sheep, Goats), By Administration Route (Intramuscular, Subcutaneous, Oral, Intranasal), By Disease Type (Bacterial Diseases, Viral Diseases, Parasitic Diseases) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.68%
- **2024:** $ 8.27 Billion
- **2025:** $ 8.57 Billion
- **2035:** $ 12.31 Billion
- **Key Players:** Companies such as Zoetis(US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) are some of the major participants in the market.

**Report ID:** MRFR/HC/40346-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** May 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/livestock-vaccine-market-42010

---

## Market Summary

## **Livestock Vaccine Market Overview**

As per MRFR analysis, the Livestock Vaccine Market Size was estimated at 7.97 USD Billion in 2023. The Livestock Vaccine Market Industry is expected to grow from 8.27 USD Billion in 2024 to 12.3 USD Billion by 2035. The Livestock Vaccine Market CAGR growth rate is expected to be around 3.68% during the forecast period 2025 - 2035.

### **Key Livestock Vaccine Market Trends Highlighted**

The Global Livestock Vaccine Market is witnessing significant growth driven by increasing awareness regarding animal health and food safety. As consumers become more cognizant of the importance of immunization against diseases, livestock producers are increasingly adopting vaccines to safeguard their herds. Additionally, the rising incidences of zoonotic diseases propel the demand for effective vaccines in livestock industries.

Regulatory frameworks promoting animal welfare and implementing rigorous health protocols also significantly contribute to the expansion of this market. These drivers create a greater need for innovative vaccination solutions that ensure livestock productivity and public health. Opportunities in the Global Livestock Vaccine Market include advancements in biotechnology and genetic engineering that can lead to the development of more effective and targeted vaccines.

There is also room for expansion in emerging markets, where increasing livestock production boosts the need for vaccination programs. The growing trend toward organic and sustainable farming practices opens avenues for vaccines that align with these approaches, offering a chance for companies to innovate. Furthermore, collaboration between veterinary pharmaceutical companies and research institutions can enhance product offerings and increase market reach.

In recent times, the focus has shifted towards developing vaccines that are not only effective but also easy to administer and cost-efficient. The trend of utilizing digital technologies for monitoring animal health has emerged, facilitating timely interventions and vaccination schedules. Integration of data analytics to assess vaccine efficacy and track disease outbreaks is becoming common, enhancing overall livestock management.

These trends reflect approach to livestock care, ensuring not just the health of individual animals but the stability of the entire food supply system. As the market continues to evolve, it remains essential to stay attuned to innovations and consumer preferences that shape the future of livestock vaccination strategies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Livestock Vaccine Market Drivers**

### **Rising Demand for Animal Protein**

The Global Livestock Vaccine Market Industry is driven largely by the Growth in global population, along with the corresponding increase in consumption of animal protein. As demographic shifts towards increased consumption of meat and milk, the livestock industry has to meet higher and higher production targets. Such increases in production require healthier animals which are only possible when there are adequate vaccination programs in place.

Farm animals need to be immunized in order to prevent diseases that would dramatically reduce their productivity. Vaccinated livestock are expected to have higher rates of survival and growth, as well as reproductive rates, all of which translate to increased livestock yields. Furthermore, as the population shifts towards healthy living and demanding quality livestock products, producers are turning to improved health management practices including vaccination.

### **Government Initiatives for Disease Control**

Government policies and initiatives aimed at controlling animal diseases are significant drivers in the Global Livestock Vaccine Market Industry. Many countries are starting to recognize the importance of animal health as a crucial aspect of their agricultural strategies. By implementing disease control measures and supporting vaccination programs, governments can prevent outbreaks that not only affect livestock health but can also pose public health risks and economic challenges.

These initiatives often come with increased funding for research and development of new vaccines, encouraging manufacturers in the livestock vaccine sector. Moreover, public awareness campaigns and educational programs about the benefits of vaccination further stimulate the market, as they lead to higher adoption rates among livestock producers.

### **Technological Advancements in Vaccine Development**

Technological advancements in vaccine development are driving significant growth in the Global Livestock Vaccine Market Industry. Innovations such as recombinant DNA technology, reverse vaccinology, and novel adjuvants are leading to the creation of more effective vaccines with fewer side effects. These advancements enhance the immune response in livestock, providing longer-lasting protection. Additionally, the emergence of personalized vaccines tailored to specific breeds or conditions provides a more effective approach toward disease management.

As these technologies continue to advance, there is an expectation of improved vaccine efficacy and safety, which will further stimulate market demand and adoption among producers.

## **Livestock Vaccine Market Segment Insights**

### **Livestock Vaccine Market Vaccine Type Insights**

The Global Livestock Vaccine Market, as segmented by Vaccine Type, showcases a diverse range of vaccine formulations catering to various livestock needs. The market's landscape is primarily dominated by Inactivated Vaccines, valued at 3.5 USD Billion in 2024 and projected to reach 5.12 USD Billion by 2035; this segment holds a significant share due to its expansive use across various livestock species, providing effective disease prevention and control.

Live Attenuated Vaccines, another prominent category, is valued at 2.0 USD Billion in 2024 and expects to grow to 3.02 USD Billion by 2035, playing a crucial role in enhancing animal immunity and particularly favored for their faster onset of immunity when used in response to outbreaks.

The Subunit Vaccines category, valued at 1.5 USD Billion in 2024 and projected to reach 2.28 USD Billion by 2035, offers advantages in reducing adverse reactions, thereby gaining traction among livestock producers aiming for safer vaccination alternatives. Lastly, the DNA Vaccines segment, with a valuation of 1.27 USD Billion in 2024 estimated to increase to 1.88 USD Billion by 2035, is recognized for its innovative approach, providing significant advancements in genetic vaccination technology which appeals to researchers and veterinary practitioners looking for next-generation vaccine solutions.

The compelling growth and expansion of each category reflect broader trends within the Global Livestock Vaccine Market, capturing a mix of not only production methodologies but also specific livestock health requirements, thereby driving market growth. Overall, each Vaccine Type serves critical purposes in animal health management, influencing the market dynamics and shaping investment opportunities across the Global Livestock Vaccine Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Livestock Vaccine Market Livestock Type Insights**

The Global Livestock Vaccine Market is expected to be valued at 8.27 billion USD in 2024, reflecting a growing emphasis on animal health and disease prevention within the livestock sector. The market segmentation by Livestock Type includes key categories such as Cattle, Poultry, Swine, Sheep, and Goats. Among these, Poultry vaccination holds major significance due to the high density of production and susceptibility to infectious diseases, driving consistent demand for effective vaccines.

Cattle also represent a substantial portion of the market as they are critical for meat and dairy production, making vaccination essential for both health and productivity. Swine vaccines are increasingly important as global pork consumption rises, necessitating robust health management strategies. Sheep and Goats, while smaller segments, contribute to niche markets that require specific vaccinations to address endemic diseases prevalent in certain regions. As a result, the overall market dynamics reflect trends toward increased vaccination efforts, influenced by factors such as expanding livestock production, rising awareness of animal health, and regulatory pressures.

This backdrop presents opportunities for growth while also highlighting challenges such as vaccine distribution in remote areas and the need for continued innovation in vaccine development.

### **Livestock Vaccine Market Administration Route Insights**

The Administration Route segment of the Global Livestock Vaccine Market plays a critical role in defining how vaccines are delivered to livestock, which is essential for ensuring effective immunization. By 2024, the overall market is expected to be valued at 8.27 billion USD. The market exhibits various methods of administration including Intramuscular, Subcutaneous, [Oral Thrush](../../../reports/oral-thrush-market-4417), and Intranasal routes. Intramuscular administration often dominates due to its effectiveness in delivering vaccines rapidly into the bloodstream, making it a preferred choice for veterinarians.

Subcutaneous administration also holds a significant share, particularly for vaccines that require slower absorption rates. Meanwhile, Oral administration offers advantages in terms of ease of use and stress reduction for animals, making it particularly suitable for some types of livestock. Intranasal administration provides a unique alternative that is gaining traction due to its non-invasive nature and ability to stimulate rapid immune responses. Together, these diverse administration routes contribute to the nuanced landscape of the Global Livestock Vaccine Market, presenting both opportunities for growth and challenges in veterinary practices as they adapt to evolving vaccination strategies.

The market growth remains driven by advancements in vaccine technology and increasing awareness among livestock producers.

### **Livestock Vaccine Market Disease Type Insights**

The Global Livestock Vaccine Market segment based on Disease Type includes critical classifications such as Bacterial Diseases, Viral Diseases, and Parasitic Diseases. In 2024, the overall market is expected to be valued at 8.27 USD Billion, reflecting a robust demand for vaccines across various livestock categories. Bacterial Diseases constitute a major portion of the market, with vaccines vital for controlling infections like mastitis in dairy cattle and avian cholera in poultry, which can lead to significant economic losses.

Similarly, Viral Diseases hold a prominent share, particularly with vaccines that combat diseases such as foot-and-mouth disease and Newcastle disease, which are crucial for maintaining healthy livestock. Parasitic Diseases are also significant; their prevention through vaccination is essential for enhancing livestock productivity and ensuring food safety. The continuous advancement in vaccine technology, increased awareness regarding animal health, and a growing global population demanding protein sources are key growth drivers for this segment. The market is poised to experience steady growth as livestock producers seek innovative and effective vaccination solutions to improve livestock health and productivity.

Factors like stringent regulations on food safety and the rising incidence of zoonotic diseases present both challenges and opportunities for the market to expand its impact.

### **Livestock Vaccine Market Regional Insights**

The Regional segment of the Global Livestock Vaccine Market showcases a diverse landscape with noteworthy valuations. In 2024, the North America market holds a prominent position, valued at 3.15 USD Billion, and is expected to rise to 4.68 USD Billion by 2035, reflecting its majority holding due to advanced livestock farming practices and technological integration in vaccine development. Europe follows closely, with a valuation of 2.32 USD Billion projected to grow to 3.2 USD Billion, benefiting from stringent regulatory standards and high livestock density.

The APAC region, valued at 2.0 USD Billion in 2024, is instrumental with significant growth potential as emerging economies increase their livestock production, expanding to 2.95 USD Billion by 2035. South America and MEA, valued at 0.84 USD Billion and 0.96 USD Billion respectively in 2024, are more modest players in the Global Livestock Vaccine Market landscape. South America's growth is driven by increasing meat export demands, while MEA’s market, anticipated to reach 1.27 USD Billion, largely thrives on rural agricultural practices and livestock health needs.

Together, these regions contribute to the evolving dynamics of the Global Livestock Vaccine Market, characterized by unique growth drivers and challenges.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Livestock Vaccine Market Key Players and Competitive Insights**

The Global Livestock Vaccine Market is characterized by a dynamic and competitive landscape, fueled by the increasing need for effective animal health management due to rising global demand for livestock products. The continuous advancements in vaccine technology and a growing awareness among livestock producers about the importance of vaccination in preventing diseases are driving competition within the market. Furthermore, regional variations in livestock production and the regulatory environment play a significant role in shaping the competitive strategies adopted by various players.

Innovations in vaccine formulations, delivery mechanisms, and targeted treatment strategies also contribute to the competitive edged within this sector, helping companies differentiate their product offerings while addressing the unique health challenges faced by livestock worldwide.

Epitopix has established a notable presence in the Global Livestock Vaccine Market through its focus on developing high-quality vaccines designed specifically for poultry, swine, and cattle. The company leverages strong research and development capabilities, enabling it to create innovative and effective vaccine solutions that meet the diverse needs of livestock producers. This commitment to scientific advancement has positioned Epitopix favorably among veterinarians and livestock producers alike, who seek reliable preventive measures against infectious diseases.

The company’s strong emphasis on customer relationships and support amplifies its market presence, as it works closely with clients to ensure the proper use of its vaccines, fostering trust and loyalty in the industry.

Vetoquinol, on the other hand, has carved out a significant niche in the Global Livestock Vaccine Market by offering a comprehensive range of veterinary products, including vaccines for various animal species. Known for its commitment to quality and safety, Vetoquinol has built a solid reputation amongst livestock producers seeking effective health management solutions. The company's extensive international reach enables it to serve a broad array of markets, from large-scale producers to smaller operations, while providing tailored vaccination programs to address specific health challenges.

Vetoquinol's strategic partnerships and collaborations with leading research institutions further enhance its capability in developing cutting-edge vaccines, making it a competitive player in the livestock health segment and ensuring its products remain relevant in a rapidly evolving market landscape.

### **Key Companies in the Livestock Vaccine Market Include**

- Epitopix
- Vetoquinol
- Cegelec
- [Boehringer Ingelheim](https://www.boehringer-ingelheim.com/au/vaccines-animals)
- Zoetis
- Novartis Animal Health
- Fatro
- MSD Animal Health
- RichterHelm Biologics
- Merck Animal Health
- Heska Corporation
- Elanco Animal Health
- Diamond Animal Health
- Virbac

### Livestock Vaccine Industry Developments

- **Q2 2024: Boehringer Ingelheim opens new veterinary vaccine production facility in France** Boehringer Ingelheim inaugurated a new €200 million facility in Lyon, France, dedicated to the production of livestock vaccines, aiming to expand its manufacturing capacity and meet growing global demand.
- **Q2 2024: Zoetis Receives European Commission Approval for New Cattle Respiratory Vaccine** Zoetis announced it has received marketing authorization from the European Commission for its new vaccine targeting bovine respiratory disease, expanding its livestock vaccine portfolio in the EU.
- **Q1 2024: Ceva Santé Animale Acquires Stake in Biovac for Livestock Vaccine Expansion** Ceva Santé Animale acquired a minority stake in Biovac, a move aimed at strengthening its position in the livestock vaccine market and expanding its product offerings in emerging markets.
- **Q2 2024: Indian Immunologicals Limited Launches New Foot-and-Mouth Disease Vaccine** Indian Immunologicals Limited launched a new vaccine for foot-and-mouth disease in cattle, designed to provide broader protection against multiple virus strains prevalent in Asia.
- **Q1 2024: Hester Biosciences gets regulatory nod for sheep pox vaccine export to Africa** Hester Biosciences received regulatory approval to export its sheep pox vaccine to several African countries, marking a significant step in its international expansion strategy.
- **Q2 2024: Merck Animal Health announces partnership with Ginkgo Bioworks to develop next-generation livestock vaccines** Merck Animal Health entered into a strategic partnership with Ginkgo Bioworks to co-develop advanced vaccines for livestock, leveraging synthetic biology to address emerging animal health threats.
- **Q1 2024: Boehringer Ingelheim appoints new Head of Global Livestock Vaccines** Boehringer Ingelheim announced the appointment of Dr. Maria Keller as the new Head of Global Livestock Vaccines, responsible for leading the company's vaccine strategy and innovation.
- **Q2 2024: Phibro Animal Health Corporation launches new swine vaccine in the United States** Phibro Animal Health Corporation introduced a new vaccine for swine respiratory disease in the U.S. market, aiming to address rising disease incidence and improve herd health outcomes.
- **Q1 2024: Zoetis completes acquisition of veterinary vaccine manufacturer Jurox** Zoetis completed its acquisition of Jurox, an Australia-based veterinary vaccine manufacturer, expanding its global footprint and product portfolio in the livestock sector.
- **Q2 2024: Virbac opens new research and development center for livestock vaccines in Brazil** Virbac inaugurated a new R&D center in Brazil focused on developing innovative vaccines for cattle and poultry, reinforcing its commitment to the Latin American livestock market.
- **Q1 2024: Elanco Animal Health secures $100 million funding to accelerate livestock vaccine innovation** Elanco Animal Health raised $100 million in new funding to support research and development of next-generation vaccines for livestock, with a focus on emerging infectious diseases.
- **Q2 2024: Ceva Santé Animale signs agreement with Kenya Veterinary Vaccines Production Institute** Ceva Santé Animale entered into an agreement with the Kenya Veterinary Vaccines Production Institute to co-develop and locally manufacture livestock vaccines for the African market.

## **Livestock Vaccine Market Segmentation Insights**

### **Livestock Vaccine Market Vaccine Type Outlook**

- Inactivated Vaccines
- Live Attenuated Vaccines
- Subunit Vaccines
- DNA Vaccines

### **Livestock Vaccine Market Livestock Type Outlook**

- Cattle
- Poultry
- Swine
- Sheep
- Goats

### **Livestock Vaccine Market Administration Route Outlook**

- Intramuscular
- Subcutaneous
- Oral
- Intranasal

### **Livestock Vaccine Market Disease Type Outlook**

- Bacterial Diseases
- Viral Diseases
- Parasitic Diseases

### **Livestock Vaccine Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Emergence of Zoonotic Diseases

The increasing incidence of zoonotic diseases, which can be transmitted from animals to humans, is a critical driver for the Livestock Vaccine Market. Recent outbreaks have highlighted the need for robust vaccination programs to mitigate risks associated with these diseases. For instance, diseases such as avian influenza and foot-and-mouth disease have prompted governments and health organizations to prioritize vaccination as a preventive measure. 
 
The World Health Organization has indicated that zoonotic diseases account for a significant percentage of emerging infectious diseases, emphasizing the importance of vaccination in livestock. This growing awareness and urgency surrounding zoonotic diseases are likely to propel the Livestock Vaccine Market forward as stakeholders seek to protect both animal and human health.

### Growing Awareness of Food Safety

The rising consumer awareness regarding food safety and quality is significantly influencing the Livestock Vaccine Market. Consumers are increasingly concerned about the origins of their food and the health of the animals from which it is derived. This heightened awareness drives demand for vaccines that ensure livestock are healthy and free from diseases that could affect food safety.
 
As a result, producers are more likely to implement comprehensive vaccination programs to meet consumer expectations and regulatory standards. The emphasis on food safety not only enhances public health but also supports the economic stability of the livestock sector. Consequently, the Livestock Vaccine Market is poised for growth as stakeholders respond to these evolving consumer demands.

### Rising Demand for Animal Protein

The increasing The Livestock Vaccine Industry. As consumers seek more meat, dairy, and eggs, livestock production must intensify, necessitating effective vaccination strategies to ensure animal health and productivity. According to recent data, the livestock sector is projected to grow significantly, with meat consumption expected to rise by over 70% by 2050.
 
This surge in demand compels farmers to adopt vaccination programs to prevent disease outbreaks that could jeopardize livestock health and production. Consequently, the Livestock Vaccine Market is likely to experience substantial growth as producers invest in vaccines to maintain herd health and meet consumer needs.

### Advancements in Vaccine Technology

Technological innovations in vaccine development are transforming the Livestock Vaccine Market. The introduction of novel vaccine platforms, such as mRNA vaccines and vector-based vaccines, offers enhanced efficacy and safety profiles. These advancements enable quicker responses to emerging diseases and improve the overall effectiveness of vaccination programs.
 
For example, the development of vaccines that provide broader protection against multiple strains of pathogens is becoming increasingly feasible. As a result, livestock producers are more inclined to invest in these advanced vaccines, which can lead to improved herd immunity and reduced disease prevalence. The ongoing research and development in vaccine technology are expected to significantly influence the Livestock Vaccine Market, fostering growth and innovation.

### Government Initiatives and Funding

Government initiatives aimed at promoting livestock health and disease prevention are pivotal for the Livestock Vaccine Market. Many countries are implementing vaccination programs supported by funding and subsidies to encourage farmers to vaccinate their livestock. These initiatives often focus on eradicating specific diseases that pose a threat to animal health and food security.
 
For instance, programs targeting diseases like brucellosis and bovine tuberculosis have received substantial government backing, which not only aids in disease control but also boosts the livestock sector's economic viability. As governments continue to prioritize animal health, the Livestock Vaccine Market is likely to benefit from increased funding and support for vaccination efforts.

## Future Outlook

The Livestock Vaccine Market size is projected to reach USD 12.31 Billion by 2035, growing at a CAGR of 3.68%, driven by increasing livestock production, disease outbreaks, and advancements in vaccine technology.

**New opportunities:**

- Development of personalized vaccines for specific livestock breeds. Expansion of digital platforms for vaccine tracking and management. Investment in research for novel adjuvants to enhance vaccine efficacy.

By 2035, the market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Vaccine Type: Inactivated Vaccines (Largest) vs. Live Attenuated Vaccines (Fastest-Growing)

The livestock vaccine market exhibits a diverse array of vaccine types, with inactivated vaccines holding a substantial market share of 52% due to their established safety and efficacy profiles. These vaccines are widely used in various livestock species, ensuring immunity against prevalent diseases. In contrast, live attenuated vaccines are rapidly gaining traction, appealing to producers because of their ability to elicit strong immune responses with fewer doses and lower overall costs, making them an increasingly attractive option for livestock health management.

Inactivated Vaccines (Dominant) vs. Live Attenuated Vaccines (Emerging)

Inactivated vaccines are known for their reliability and safety, making them the dominant choice among livestock producers. These vaccines are produced using killed pathogens, ensuring there is no risk of disease transmission, which is a critical consideration in animal husbandry. On the other hand, live attenuated vaccines are emerging as a powerful alternative, as they stimulate a strong immune response and provide long-lasting immunity, often requiring fewer doses. Their ability to penetrate various pathogen strains makes them a compelling option for farmers seeking to optimize livestock health while managing production costs.

### By Livestock Type: Cattle (Largest) vs. Poultry (Fastest-Growing)

In the livestock vaccine market, the distribution of market share among the various livestock types indicates a significant dominance by cattle, which remains the largest segment holding market share of 48% due to its extensive commercial importance. This segment benefits from a well-established vaccination infrastructure and a strong demand for cattle-based products, which amplifies its share in the overall market. Conversely, poultry is emerging as the fastest-growing segment due to the increasing global demand for poultry products, driven by changing consumer preferences towards protein sources especially in developing regions.

Cattle (Dominant) vs. Poultry (Emerging)

Cattle vaccines dominate the livestock vaccine market owing to the critical role they play in safeguarding herd health and productivity. The prevalence of diseases in cattle can have catastrophic effects on both animal welfare and economic productivity, driving continual investments in vaccine development. On the other hand, poultry vaccines are rapidly gaining traction as the segment responds to the surge in poultry consumption worldwide. The emergence of new diseases such as avian influenza has spurred innovation and urgency in vaccine production for poultry, ensuring that this segment is positioned for significant growth, reflecting the shifting paradigms in global meat consumption.

### By Administration Route: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

The livestock vaccine market exhibits a diverse range of administration routes, with intramuscular administration accounting for the largest market share of 56%. This method is preferred due to its effective absorption and rapid immune response in livestock. Subcutaneous vaccines are also significant, capturing a growing share as they provide an accessible alternative with minimal discomfort for animals. Oral and intranasal routes, while effective, account for smaller portions of the overall market share. Recent trends indicate a shift towards the subcutaneous administration route, which is quickly gaining traction among veterinarians and livestock producers. This growth is driven by advancements in vaccine technology and formulation that enhance efficacy and ease of administration. Increasing awareness of animal health and welfare further fuels the demand for innovative vaccine delivery methods beyond traditional approaches, ensuring stronger immunity and better overall herd health.

Intramuscular (Dominant) vs. Oral (Emerging)

Intramuscular administration remains the dominant route in the livestock vaccine market, favored for delivering vaccines directly into the muscle, ensuring rapid absorption and robust immune response. This method is highly efficient for a variety of livestock species, including cattle, swine, and poultry. On the other hand, oral administration is emerging as an innovative alternative, particularly for enabling ease of use in mass vaccination programs. With ongoing research and development focused on optimizing oral formulations, this method offers significant advantages in terms of reducing stress on animals and simplifying vaccination processes. The adaptability of both routes highlights the importance of considering specific farm management practices and livestock characteristics when selecting the appropriate vaccine administration method.

### By Disease Type: Bacterial Diseases (Largest) vs. Viral Diseases (Fastest-Growing)

The Livestock Vaccine Market is distinctly segmented by disease type, with bacterial diseases commanding the largest market share of 51% This segment includes vaccines that are essential for preventing diseases such as foot-and-mouth disease and pneumonia, contributing significantly to the overall revenues in the livestock sector. Conversely, viral diseases represent the fastest-growing segment due to the increasing prevalence of viral infections like avian influenza and Newcastle disease, which have seen a surge in outbreaks in recent years.

Bacterial Diseases (Dominant) vs. Viral Diseases (Emerging)

Bacterial diseases, including those caused by pathogens like Brucella and Mycoplasma, remain dominant within the livestock vaccine market due to the longstanding need for immunization against well-established infections that affect livestock health and productivity. The demand for these vaccines arises from the need to mitigate the economic losses associated with these diseases. In contrast, viral diseases have emerged as a critical area of focus for vaccine development due to the rapid evolution of viruses and the increasing incidence of outbreaks. This segment is characterized by innovation in vaccine technology and heightened investment from pharmaceutical companies aiming to address the urgent need for effective antiviral strategies to protect livestock.

## Regional Market Share Analysis

The Regional segment of the Global Livestock Vaccine Market showcases a diverse landscape with noteworthy valuations. In 2024, the North America leads in the Livestock Vaccine Market size, accounting for over 39.90% of the global revenue in 2024, and is expected to rise to 4.68 USD Billion by 2035, reflecting its majority holding due to advanced livestock farming practices and technological integration in vaccine development. North America’s market leadership is driven by advanced livestock farming systems, technological innovation in veterinary healthcare, and strong preventive vaccination practices.

- According to Centers for Disease Control and Prevention, **75% of emerging infectious diseases affecting humans originate in animals**, reinforcing the importance of livestock vaccination programs to prevent disease transmission, improve herd health, and maintain food security.

Europe Livestock Vaccine Market size was valued at USD 2.32 Billion in 2024, making it the second-largest regional market with a 28.05% share, benefiting from stringent regulatory standards and high livestock density. Europe’s growth is supported by stringent animal health regulations, high livestock density, and increasing emphasis on food safety standards.

- The European region maintains strong focus on animal disease prevention and sustainable agriculture. Enhanced livestock vaccination strategies help reduce disease outbreaks while supporting productivity, aligning with stricter regulatory frameworks and increasing consumer demand for safe animal-derived products.

The APAC region, valued at 2.0 USD Billion in 2024, is instrumental with significant growth potential as emerging economies increase their livestock production, expanding to 2.95 USD Billion by 2035. South America and MEA, valued at 0.84 USD Billion and 0.96 USD Billion respectively in 2024, are more modest players in the Global Livestock Vaccine Market landscape. South America's growth is driven by increasing meat export demands, while MEA’s market, anticipated to reach 1.27 USD Billion, largely thrives on rural agricultural practices and livestock health needs.

Together, these regions contribute to the evolving dynamics of the Global Livestock Vaccine Market, characterized by unique growth drivers and challenges.

## Competitive Benchmarking

The Global Livestock Vaccine Market is characterized by a dynamic and competitive landscape, fueled by the increasing need for effective animal health management due to rising global demand for livestock products. The continuous advancements in vaccine technology and a growing awareness among livestock producers about the importance of vaccination in preventing diseases are driving competition within the market. Furthermore, regional variations in livestock production and the regulatory environment play a significant role in shaping the competitive strategies adopted by various players. 
 
Innovations in vaccine formulations, delivery mechanisms, and targeted treatment strategies also contribute to the competitive edged within this sector, helping companies differentiate their product offerings while addressing the unique health challenges faced by livestock worldwide. Epitopix has established a notable presence in the Global Livestock Vaccine Market through its focus on developing high-quality vaccines designed specifically for poultry, swine, and cattle.
 
The company leverages strong research and development capabilities, enabling it to create innovative and effective vaccine solutions that meet the diverse needs of livestock producers. This commitment to scientific advancement has positioned Epitopix favorably among veterinarians and livestock producers alike, who seek reliable preventive measures against infectious diseases.
 
The company’s strong emphasis on customer relationships and support amplifies its market presence, as it works closely with clients to ensure the proper use of its vaccines, fostering trust and loyalty in the industry. Vetoquinol, on the other hand, has carved out a significant niche in the Global Livestock Vaccine Market by offering a comprehensive range of veterinary products, including vaccines for various animal species. Known for its commitment to quality and safety, Vetoquinol has built a solid reputation amongst livestock producers seeking effective health management solutions.
 
The company's extensive international reach enables it to serve a broad array of markets, from large-scale producers to smaller operations, while providing tailored vaccination programs to address specific health challenges. Vetoquinol's strategic partnerships and collaborations with leading research institutions further enhance its capability in developing cutting-edge vaccines, making it a competitive player in the livestock health segment and ensuring its products remain relevant in a rapidly evolving market landscape.

## Recent News & Developments

- **Q2 2024: Boehringer Ingelheim opens new veterinary vaccine production facility in France** Boehringer Ingelheim inaugurated a new €200 million facility in Lyon, France, dedicated to the production of livestock vaccines, aiming to expand its manufacturing capacity and meet growing global demand.
- **Q2 2024: Zoetis Receives European Commission Approval for New Cattle Respiratory Vaccine** Zoetis announced it has received marketing authorization from the European Commission for its new vaccine targeting bovine respiratory disease, expanding its livestock vaccine portfolio in the EU.
- **Q1 2024: Ceva Santé Animale Acquires Stake in Biovac for Livestock Vaccine Market Expansion** Ceva Santé Animale acquired a minority stake in Biovac, a move aimed at strengthening its position in the livestock vaccine market and expanding its product offerings in emerging markets.
- **Q2 2024: Indian Immunologicals Limited Launches New Foot-and-Mouth Disease Vaccine** Indian Immunologicals Limited launched a new vaccine for foot-and-mouth disease in cattle, designed to provide broader protection against multiple virus strains prevalent in Asia.
- **Q1 2024: Hester Biosciences gets regulatory nod for sheep pox vaccine export to Africa** Hester Biosciences received regulatory approval to export its sheep pox vaccine to several African countries, marking a significant step in its international expansion strategy.
- **Q2 2024: Merck Animal Health announces partnership with Ginkgo Bioworks to develop next-generation livestock vaccines** Merck Animal Health entered into a strategic partnership with Ginkgo Bioworks to co-develop advanced vaccines for livestock, leveraging synthetic biology to address emerging animal health threats.
- **Q1 2024: Boehringer Ingelheim appoints new Head of Global Livestock Vaccines** Boehringer Ingelheim announced the appointment of Dr. Maria Keller as the new Head of Global Livestock Vaccines, responsible for leading the company's vaccine strategy and innovation.
- **Q2 2024: Phibro Animal Health Corporation launches new swine vaccine in the United States** Phibro Animal Health Corporation introduced a new vaccine for swine respiratory disease in the U.S. market, aiming to address rising disease incidence and improve herd health outcomes.
- **Q1 2024: Zoetis completes acquisition of veterinary vaccine manufacturer Jurox** Zoetis completed its acquisition of Jurox, an Australia-based veterinary vaccine manufacturer, expanding its global footprint and product portfolio in the livestock sector.
- **Q2 2024: Virbac opens new research and development center for livestock vaccines in Brazil** Virbac inaugurated a new R&D center in Brazil focused on developing innovative vaccines for cattle and poultry, reinforcing its commitment to the Latin American livestock market.
- **Q1 2024: Elanco Animal Health secures $100 million funding to accelerate livestock vaccine innovation** Elanco Animal Health raised $100 million in new funding to support research and development of next-generation vaccines for livestock, with a focus on emerging infectious diseases.
- **Q2 2024: Ceva Santé Animale signs agreement with Kenya Veterinary Vaccines Production Institute** Ceva Santé Animale entered into an agreement with the Kenya Veterinary Vaccines Production Institute to co-develop and locally manufacture livestock vaccines for the African market.

## Report Scope

| MARKET SIZE 2024 | 8.27(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 8.574(USD Billion) |
| MARKET SIZE 2035 | 12.31(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.68% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) |
| Segments Covered | Vaccine Type, Livestock Type, Administration Route, Disease Type, Regional |
| Key Market Opportunities | Advancements in biotechnology enhance efficacy and safety in the Livestock Vaccine Market. |
| Key Market Dynamics | Rising demand for livestock vaccines driven by regulatory changes and technological advancements in animal health management. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Livestock Vaccine Market as of 2024?**
A: The Livestock Vaccine Market was valued at 8.27 USD Billion in 2024.

**Q: What is the projected market valuation for the Livestock Vaccine Market in 2035?**
A: The market is projected to reach 12.31 USD Billion by 2035.

**Q: What is the expected CAGR for the Livestock Vaccine Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Livestock Vaccine Market during 2025 - 2035 is 3.68%.

**Q: Which livestock type is expected to generate the highest revenue in the Livestock Vaccine Market?**
A: Poultry is anticipated to generate the highest revenue, with a projected valuation of 4.0 USD Billion by 2035.

**Q: What are the key segments of the Livestock Vaccine Market based on vaccine type?**
A: Key segments include Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and DNA Vaccines.

**Q: Which company is a leading player in the Livestock Vaccine Market?**
A: Zoetis, based in the US, is recognized as a leading player in the Livestock Vaccine Market.

**Q: What is the projected revenue for DNA Vaccines by 2035?**
A: DNA Vaccines are projected to reach a valuation of 3.81 USD Billion by 2035.

**Q: How does the revenue from bacterial diseases compare to viral diseases in the Livestock Vaccine Market?**
A: Revenue from viral diseases is expected to be higher, projected at 4.92 USD Billion by 2035, compared to 3.67 USD Billion for bacterial diseases.

**Q: What administration route is expected to have the highest revenue in the Livestock Vaccine Market?**
A: The intramuscular administration route is projected to generate the highest revenue, reaching 3.66 USD Billion by 2035.

**Q: What is the expected revenue for swine vaccines by 2035?**
A: Swine vaccines are projected to reach a valuation of 2.0 USD Billion by 2035.

**Q: What is the market size of the Global Livestock Vaccine Market in 2024?**
A: The Global Livestock Vaccine Market is expected to be valued at 8.77 USD Billion in 2024.

**Q: What is the projected market growth rate for the Global Livestock Vaccine Market from 2025 to 2035?**
A: The market is expected to grow at a CAGR of 4.82% from 2025 to 2035.

**Q: Which application segment holds the largest market share in 2024?**
A: In 2024, the Cattle segment is projected to be valued at 3.5 USD Billion, making it the largest application segment.

**Q: How much is the Poultry application segment expected to grow by 2035?**
A: The Poultry application segment is expected to reach 4.3 USD Billion by 2035.

**Q: What is the market size for the Swine application segment in 2024?**
A: The Swine application segment is valued at 1.2 USD Billion in 2024.

**Q: Which region will have the highest market value in 2035?**
A: North America is projected to have the highest market value of 5.05 USD Billion in 2035.

**Q: What will be the market size of Europe in 2035?**
A: The market size for Europe is expected to reach 4.1 USD Billion by 2035.

**Q: Which companies are identified as major players in the Global Livestock Vaccine Market?**
A: Major players include Biogenesis Bago, Merck Animal Health, and Zoetis among others.

**Q: What is the expected market value for Aquaculture vaccines in 2035?**
A: The Aquaculture segment is expected to reach a market value of 1.5 USD Billion by 2035.

**Q: How much is the MEA region expected to grow by 2035?**
A: The MEA region is projected to grow to 0.77 USD Billion in 2035, up from 0.17 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/livestock-vaccine-market-42010*